Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07826390
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
PF-07826390 is an investigational bispecific IgG1 monoclonal antibody developed by Pfizer. It targets both leukocyte immunoglobulin-like receptor B1 (LILRB1, also known as ILT2) and leukocyte immunoglobulin-like receptor B2 (LILRB2, also known as ILT4), which are expressed on myeloid cells in the tumor microenvironment. By blocking these receptors, PF-07826390 aims to overcome immune suppression and resistance to PD-(L)1 inhibitors in cancer therapy. The drug is being evaluated for safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity as a single agent or in combination with sasanlimab in patients with advanced solid tumors such as non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and renal cell carcinoma (RCC).
- Other names
- LILRB1/2 bispecific IgG1 antibodyanti-ILT2/anti-ILT4 bispecific antibody
02
Targets
LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)LILRB2 (Leukocyte immunoglobulin-like receptor subfamily B member 2)
Beyond the preview
Go deeper on PF-07826390.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07826390.